Miller Steve sold (to issuer) $34.5M of CPRX
Miller Steve (Chief Op. & Scientific Officer) sold (to issuer) 1,093,803 shares of CATALYST PHARMACEUTICALS, INC. (CPRX) at $31.50 ($34.45M total) on 2026-07-15.
How this was made
The 30-second read
Why it matters
The disclosed event is a single insider sale to the issuer totaling about $34.45M, with holdings after transaction reported as 0 shares.
Market read
Traders may monitor for follow-on selling pressure or sentiment effects, but there is no new clinical, regulatory, or financial datapoint here.
What to watch
The article does not state whether the sale was part of compensation, tax planning, or other non-informational motives; absence of a 10b5-1 plan is notable but not determinative.
Background
The article is an SEC Form 4 insider transaction disclosure for Catalyst Pharmaceuticals (CPRX).
Ticker impact
Catalyst Pharmaceuticals insider Steve Miller sold 1,093,803 shares to the issuer at $31.50 on 2026-07-15, totaling about $34.45M.
Likely limited, short-lived sentiment impact; no direct operational or guidance change disclosed.
The filing is a Form 4 insider transaction with sale-to-issuer code D and no 10b5-1 plan stated, but it does not provide new company performance or regulatory/clinical catalysts.
Market effects
Minimal read-across for biotech sector; this is an issuer-specific insider liquidity transaction.
None indicated.
None indicated.
Counterpoint
A sale to the issuer can be routine (tax/plan mechanics) and may not reflect bearish expectations, especially without any accompanying negative news in the filing.
Key entities
- issuerCatalyst Pharmaceuticals, Inc.
CPRX, the company that received the insider sale to issuer (code D).
- insiderSteve Miller
Chief Op. and Scientific Officer who sold 1,093,803 shares at $31.50.